RESEARCH PROFILE
KLOW
GHK-Cu + KPV + BPC-157 + TB-500 • Tissue & Inflammatory Research Blend
KLOW is a four-compound research blend combining GHK-Cu, KPV, BPC-157, and TB-500 within a single framework focused on skin and extracellular-matrix biology, connective-tissue repair, inflammatory signaling, cell migration, and gut-related research pathways.
It builds on the GLOW framework by adding KPV, an alpha-MSH-derived tripeptide studied primarily for anti-inflammatory and intestinal-barrier signaling.
INVESTIGATIONAL BLEND • NOT FDA APPROVED • COMBINATION NOT CLINICALLY VALIDATED
KLOW AT A GLANCE
Category
Skin, tissue repair, and inflammatory research blend
Components
GHK-Cu + KPV + BPC-157 + TB-500
Standard Research Formulation
50 mg GHK-Cu + 10 mg KPV + 10 mg BPC-157 + 10 mg TB-500
Total Nominal Vial Content
80 mg
Primary Research Focus
Skin remodeling • Tissue repair • Inflammatory signaling • Cell migration • Gut-barrier biology
Evidence Base
Compound-level human, animal, and laboratory research
Combination Evidence
No published human trial evaluating all four compounds together
Regulatory Status
KLOW is not an FDA-approved drug
IMPORTANT DISTINCTION
KLOW is not simply another name for GLOW.
GLOW contains:
GHK-Cu
BPC-157
TB-500
KLOW contains those same three compounds plus KPV.
The addition of KPV shifts the research rationale toward inflammatory signaling and gut-barrier biology in addition to the skin and tissue-repair pathways already represented in GLOW.
No clinical trial has demonstrated that adding KPV makes the blend safer, more effective, or clinically superior.
WHAT IS THE KLOW BLEND?
KLOW is a research-community blend combining four peptides or peptide-related compounds:
GHK-Cu
KPV
BPC-157
TB-500
Your Project profile describes the standard formulation as:
50 / 10 / 10 / 10 mg
with GHK-Cu representing the largest component.
GHK-Cu
GHK-Cu is a naturally occurring copper-binding tripeptide associated with research involving:
Collagen synthesis
Elastin
Skin remodeling
Gene expression
Extracellular matrix
Wound-repair pathways
KPV
KPV is a three-amino-acid fragment of alpha-MSH.
Research focuses on:
NF-κB signaling
Inflammatory pathways
PepT1-mediated intestinal uptake
Gut-barrier biology
Antimicrobial activity
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide studied largely in preclinical models involving:
Tendon biology
Ligament biology
Angiogenesis
Cell migration
Gastrointestinal tissue
Soft-tissue repair
TB-500
TB-500 is associated with a functional region of thymosin beta-4 and is researched in relation to:
Actin biology
Cell migration
Angiogenesis
Tissue remodeling
Repair signaling
WHY COMBINE THEM?
The KLOW concept adds an inflammation-focused research layer to the repair and skin-remodeling framework already represented by GLOW.
This creates a broader mechanistic research model.
It does not establish clinical synergy.
MECHANISM OF ACTION
KLOW combines four distinct research pathways.
GHK-Cu — SKIN & MATRIX REMODELING
GHK-Cu research has examined:
Collagen synthesis
Elastin
Decorin
Glycosaminoglycans
Matrix metalloproteinases
Gene expression
Its role in KLOW is primarily related to skin quality and extracellular-matrix remodeling.
KPV — ANTI-INFLAMMATORY SIGNALING
KPV provides the clearest inflammation-focused component of the blend.
Preclinical research has investigated:
NF-κB inhibition
PepT1-mediated uptake
MAP kinase signaling
Inflammatory cytokine pathways
Gut epithelial biology
This differentiates KLOW from GLOW.
BPC-157 — REPAIR SIGNALING
Preclinical BPC-157 research has explored:
VEGF-related signaling
Angiogenesis
Cell migration
FAK and ERK pathways
Tendon and connective-tissue repair
Its proposed role is primarily related to local repair signaling.
TB-500 — ACTIN & CELL MIGRATION
TB-500-related research focuses heavily on:
Actin dynamics
Cell movement
Angiogenesis
Tissue remodeling
Connective-tissue organization
COMPLEMENTARY PATHWAY CONCEPT
The proposed KLOW model can be summarized as:
GHK-Cu
Skin and matrix remodeling
KPV
Inflammatory and gut-barrier signaling
BPC-157
Repair and angiogenic signaling
TB-500
Actin, cell migration, and tissue remodeling
IMPORTANT MECHANISM LIMITATION
The rationale is mechanism-based.
No published human trial has established that the four compounds act synergistically when administered together.
A broader pathway map does not automatically mean a better clinical outcome.
WHAT THE RESEARCH SHOWS
KLOW COMBINATION EVIDENCE
The most important evidence boundary is:
No published human clinical trial identified in the Project source has evaluated GHK-Cu + KPV + BPC-157 + TB-500 together.
Claims about the blend must therefore be derived from individual-compound research.
GHK-Cu EVIDENCE
GHK-Cu has the strongest direct human evidence in the blend for topical skin-related outcomes.
Human research has examined:
Skin density
Collagen
Fine lines
Skin laxity
Skin appearance
Injectable GHK-Cu does not have an equivalent human evidence base.
KPV EVIDENCE
KPV research is predominantly preclinical.
Studies have examined:
Inflammatory bowel disease models
PepT1 intestinal transport
NF-κB signaling
Epithelial inflammation
Antimicrobial activity
Your Project source identifies no completed human KPV trial establishing clinical efficacy.
BPC-157 EVIDENCE
BPC-157 research remains predominantly animal and laboratory based.
Studies have investigated:
Tendon repair
Ligament repair
Muscle injury
Gastrointestinal tissue
Angiogenic signaling
Cell migration
Human evidence remains limited.
TB-500 / THYMOSIN BETA-4 EVIDENCE
Human research exists for full-length thymosin beta-4, but the TB-500 fragment itself has far less direct human evidence.
Preclinical research has investigated:
Cell migration
Angiogenesis
Wound repair
Cardiac repair
Connective-tissue organization
Full-length thymosin beta-4 evidence should not automatically be attributed to TB-500.
INFLAMMATORY RESEARCH
The defining addition to KLOW is KPV.
KPV's preclinical work involving NF-κB and intestinal inflammatory signaling gives KLOW a broader inflammation-related research rationale than GLOW.
However, there is no human trial showing that KLOW reduces inflammation clinically.
SKIN & CONNECTIVE-TISSUE RESEARCH
GHK-Cu contributes the strongest skin-related research.
BPC-157 and TB-500-related biology adds a repair and remodeling rationale.
Again, these separate evidence bases do not create direct evidence for the four-compound blend.
IMPORTANT EVIDENCE LIMITATION
There is no published human evidence establishing that KLOW:
Treats inflammatory disease
Improves autoimmune disorders
Heals tendons or ligaments
Repairs intestinal tissue
Improves skin quality systemically
Improves scars
Accelerates injury recovery
Outperforms GLOW or Wolverine
The proposed benefits remain compound-derived research hypotheses.
SAFETY & RESEARCH CONSIDERATIONS
There is no published human safety study evaluating the four-compound KLOW blend.
Safety must therefore be considered from the individual compounds, theoretical pathway interactions, product quality, and the absence of long-term combination data.
INJECTION-SITE EFFECTS
The Project profile identifies commonly reported local effects such as:
Redness
Mild swelling
Injection-site sensitivity or irritation
These observations do not constitute a controlled adverse-event database for KLOW.
COPPER ACCUMULATION
GHK-Cu introduces systemic copper exposure.
Your Project source identifies prolonged continuous use without off-periods as a theoretical concern for copper accumulation.
Particular caution is relevant with:
Wilson's disease
Other copper-metabolism disorders
Significant liver disease
High copper exposure from other sources
ANGIOGENESIS
BPC-157 and TB-500-related research includes angiogenic signaling.
Angiogenesis is important for normal tissue repair but is also involved in tumor biology.
Your Project source therefore identifies active malignancy or significant cancer history as an important theoretical safety concern.
This does not establish that KLOW causes cancer.
IMMUNE & INFLAMMATORY SIGNALING
KPV is specifically researched for immune and inflammatory modulation.
Long-term consequences of repeated systemic manipulation of these pathways have not been adequately characterized in humans.
UNKNOWN INTERACTIONS
No pharmacokinetic study has evaluated how all four components behave when administered together.
Potential concerns include:
Unexpected interactions
Additive biological effects
Different absorption or clearance
Dose-response changes
Unknown long-term effects
PRODUCT QUALITY
A four-compound blend introduces additional manufacturing complexity.
Potential issues include:
Incorrect ratio
Incorrect identity
Under-dosing
Over-dosing
Contamination
Stability differences
Sterility failure
Lot-specific analytical testing is particularly important for multi-compound blends.
PREGNANCY & BREASTFEEDING
The Project source identifies insufficient safety information to support the combination in pregnancy or breastfeeding.
REGULATORY CONTEXT
KLOW IS NOT FDA APPROVED
KLOW is not an FDA-approved drug, combination drug, or therapeutic product.
Pre-blending four compounds does not change the regulatory status of the individual ingredients.
GHK-Cu
Injectable GHK-Cu is not an FDA-approved therapeutic drug.
Its use in topical cosmetic products does not establish approval for injection.
KPV
KPV is not FDA approved.
Your Project source documents FDA compounding-related review involving KPV free base and KPV acetate.
BPC-157
BPC-157 is not FDA approved.
TB-500
TB-500 is not FDA approved.
Research involving full-length thymosin beta-4 does not establish approval of the TB-500 fragment.
COMPOUNDING CONTEXT
Your Project profile notes changing FDA and 503A/503B compounding-related status for individual components.
Those regulatory frameworks should be checked separately and should not be generalized to the KLOW blend as a whole.
ANTI-DOPING STATUS
Your Project source identifies BPC-157 and TB-500-related substances as prohibited under applicable World Anti-Doping Agency rules.
The presence of those ingredients makes the KLOW blend incompatible with a simple “permitted for tested athletes” characterization.
IMPORTANT REGULATORY DISTINCTION
Research blend ≠ approved combination drug
Compounding eligibility ≠ FDA approval
Cosmetic use ≠ injectable drug approval
Individual-compound research ≠ validation of the KLOW blend
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation only for specific samples and lots that can be matched to corresponding laboratory reports.
KLOW 80 MG
Laboratory
Optiq Health Labs
Sample Name
Klow 80mg
Lot
ld070292026-1
Sample ID
1273.OPT.260910
Sample Matrix
Lyophilized Peptide
Intended Use
Research Use Only
Report Date
September 18, 2026
Nominal KLOW Formulation in Project Profile
GHK-Cu: 50 mg
KPV: 10 mg
BPC-157: 10 mg
TB-500: 10 mg
Laboratory Reported Component Content
49.88 / 10.17 / 10.33 / 9.86 mg/vial
Reported Purity
99.4%
Identity
BPC-157 + GHK-Cu + TB-500 + KPV
LC-MS Confirmation • Tested
Endotoxin
Pass • LAL ≤ 0.05 EU/mg
Sterility
Pass • USP <71> • No Growth COAs-2(2)
IMPORTANT COMPONENT-ORDER NOTE
The KLOW Project profile defines the blend as:
50 mg GHK-Cu + 10 mg KPV + 10 mg BPC-157 + 10 mg TB-500
The laboratory report lists the analytes as:
BPC-157 + GHK-Cu + TB-500 + KPV
and separately reports:
49.88 / 10.17 / 10.33 / 9.86 mg/vial. COAs-2(2)
Because the reported analyte order and the expected 50/10/10/10 formulation create an ambiguity about which numerical result corresponds to which named component, I would not assign the four measured amounts to individual peptides on the website until the laboratory or supplier confirms the intended analyte order.
The safest public presentation is to display the values exactly as reported and link the full original COA.
IMPORTANT COA LIMITATION
Analytical results apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before analytical documentation is represented as supporting a product.
A passing COA does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
GHK-Cu RESEARCH
Pickart L, Margolina A.
A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
International Journal of Molecular Sciences. 2018.
Review examining GHK-Cu gene expression and regenerative biology.
Pickart L.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.
BioMed Research International. 2015.
Skin-remodeling and signaling research.
Dou Y, et al.
Research examining GHK as an anti-aging peptide.
KPV RESEARCH
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al.
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation.
Gastroenterology. 2008.
Preclinical KPV research identifying intestinal uptake and anti-inflammatory signaling.
Brzoska T, Luger TA, Maaser C, et al.
Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.
Research context for alpha-MSH-derived anti-inflammatory peptides.
Xiao B, Xu Z, Viennois E, et al.
Research examining orally targeted nanoparticle delivery of KPV in experimental colitis.
BPC-157 RESEARCH
Vanežić N, et al.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Systematic review emphasizing the largely preclinical nature of the musculoskeletal evidence.
Various authors
Review of BPC-157 in musculoskeletal-healing research.
THYMOSIN BETA-4 / TB-500 RESEARCH
Malinda KM, Sidhu GS, Mani H, et al.
Thymosin beta-4 accelerates wound healing.
Journal of Investigative Dermatology. 1999.
Preclinical wound-healing research.
Goldstein AL, Hannappel E, Sosne G, Kleinman HK.
Thymosin beta-4: a multi-functional regenerative peptide.
Review of thymosin beta-4 biology.
Sosne G, Qiu P, Goldstein AL, Wheater M.
Research examining thymosin beta-4 in corneal wound healing and inflammation.
REGULATORY REFERENCES
U.S. Food & Drug Administration
503A Bulks List and compounding-related materials relevant to KLOW components.
World Anti-Doping Agency
Current Prohibited List.
EVIDENCE NOTE
These references establish individual-compound research context.
They do not establish the safety or efficacy of the four-compound KLOW blend.
No published human clinical trial identified in the Project source has evaluated GHK-Cu + KPV + BPC-157 + TB-500 together.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish KLOW as safe or effective for personal use.
KLOW combines GHK-Cu, KPV, BPC-157, and TB-500 within a research framework involving skin biology, tissue repair, inflammatory signaling, extracellular-matrix remodeling, gut-barrier research, and cell migration.
The four compounds have substantially different evidence bases. Human evidence is strongest for topical GHK-Cu, while KPV, BPC-157, and TB-500-related claims rely heavily on animal, laboratory, mechanistic, or parent-peptide research.
KLOW itself is not FDA approved, and no published human clinical trial identified in the Project source has established the safety, efficacy, or superiority of the four-compound combination.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.